Relevance of Health Economics in Breast Cancer Treatment: Integration of Economics in the Management of Breast Cancer at the Clinic Level
Open Access
- 18 February 2013
- journal article
- review article
- Published by S. Karger AG in Breast Care
- Vol. 8 (1) , 7-14
Abstract
Since the introduction of the diagnosis-related groups (DRG) system with cost-related and entity-specific flat-rate reimbursements for all in-patients in 2004 in Germany, economics have become an important focus in medical care, including breast centers. Since then, physicians and hospitals have had to gradually take on more and more financial responsibilities for their medical care to avoid losses for their institutions. Due to financial limitations of resources, most medical services have to be adjusted to correlating revenues, which results in the development of a variety of active measures to understand, steer, and optimize costs, resources and related processes for breast cancer treatment. In this review, the challenging task to implement microeconomic management at the clinic level for breast cancer treatment is analyzed from breast cancer-specific publications. The newly developed economic management perspective is identified for different stakeholders in the healthcare system, and successful microeconomic projects and future aspects are described.Keywords
This publication has 37 references indexed in Scilit:
- Fallpauschalenentwicklung in der rekonstruktiven MammachirurgieHandchirurgie · Mikrochirurgie · Plastische Chirurgie, 2012
- Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modalityBMC Cancer, 2011
- Financial Quality Control of In-Patient Chemotherapy in Germany: Are Additional Payments Cost-Covering for Pharmaco-Oncological Expenses?Breast Care, 2011
- Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care SystemBreast Care, 2011
- Underfinancing of 90.3% for Implant Costs of Prostheses and Expanders in DRG Revenues for Uni- and Bilateral Mastectomy with Immediate Breast ReconstructionOnkologie, 2010
- Are Certified Breast Centers Cost-Effective?Breast Care, 2009
- The Costs of Treating Breast Cancer in the USPharmacoEconomics, 2009
- Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the WorldBreast Care, 2008
- Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in GermanyBreast Care, 2006
- Modell eines aktiven Kostenmanagements gynäkoonkologischer Therapien zur Reduktion der Medikamentenkosten um 58,7 % innerhalb eines JahresGeburtshilfe und Frauenheilkunde, 2005